Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Michał Pochopień"'
Autor:
Michal Pochopien, Annette Beiderbeck, Phil McEwan, Richard Zur, Mondher Toumi, Samuel Aballéa
Publikováno v:
BMC Health Services Research, Vol 19, Iss 1, Pp 1-14 (2019)
Abstract Background Diabetic macular oedema (DMO) may lead to visual loss and blindness. Several pharmacological treatments are available on the National Health Service (NHS) to United Kingdom patients affected by this condition, including intravitre
Externí odkaz:
https://doaj.org/article/974805edcdf54056967f31058fcffe78
Autor:
Sara W. Quist, Alexander V. van Schoonhoven, Stephan J. L. Bakker, Michał Pochopień, Maarten J. Postma, Jeanni M. T. van Loon, Jeroen H. J. Paulissen
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-16 (2023)
Abstract Background In the Netherlands, more than one million patients have type 2 diabetes (T2D), and approximately 36% of these patients have chronic kidney disease (CKD). Yearly medical costs related to T2D and CKD account for approximately €1.3
Externí odkaz:
https://doaj.org/article/f0123344ab7a47149b04a791e10d6a10
The impact of amortization of gene therapies funding on the results and conclusions of CEMs and BIMs
Autor:
Hubert Polek, Justyna Janik, Ewelina Paterak, Monique Dabbous, Michał Pochopień, Mondher Toumi
Publikováno v:
Journal of Market Access & Health Policy, Vol 11, Iss 1 (2023)
ABSTRACTBackground: Gene replacement therapy (GRT) is a treatment method used to combat or prevent various diseases. Its high one-off cost constitutes a major obstacle for successful market access. This paper aims to assess and discuss the applicabil
Externí odkaz:
https://doaj.org/article/b0d9fcd2aab04c4a88bf0a59c90de313
Autor:
Michał Pochopień, Ewelina Paterak, Emilie Clay, Justyna Janik, Samuel Aballea, Małgorzata Biernikiewicz, Mondher Toumi
Publikováno v:
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
Background: Gene therapies can treat, prevent, or cure a disease by changing the expression of a person’s genes. They are an innovative strategy for treating genetic disorders; however, they are still emerging on the market access and in the health
Externí odkaz:
https://doaj.org/article/754b4c674be641ef872d82a64d8b4e17
Autor:
Tingting, Qiu, Michał, Pochopień, Eve, Hanna, Shuyao, Liang, Yitong, Wang, Ru, Han, Mondher, Toumi, Samuel, Aballéa
Publikováno v:
Regenerative Medicine. 17:119-139
Aim: Regenerative medicines (RMs) are expected to transform the treatment paradigm of rare, life-threatening diseases, while substantial challenges impede its market access. This study aimed to present these challenges. Materials & methods: Publicati
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 21:1145-1158
The limited evidence in the clinical trials of gene therapies (GTs) posed substantial challenges for a reliable health technology assessment (HTA). This paper provides insights into the relationship between the background of diseases and the health e
Autor:
Michał, Pochopień, David Z I, Cherney, Aleksandra, Drzewiecka, Kerstin, Folkerts, Pierre, Levy, Aurélie, Millier, Stephen, Morris, Monika, Palarczyk, Prabir, Roy-Chaudhury, Sean D, Sullivan, Paul, Mernagh
Publikováno v:
The American journal of managed care. 28
The FINE-CKD model was developed to estimate the cost-effectiveness of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).To perform internal and external validation by comparing the model estimates with trial results
Autor:
Małgorzata Biernikiewicz, Michał Pochopień, Emilie Clay, Ewelina Paterak, Mondher Toumi, Justyna Janik, Samuel Aballéa
Publikováno v:
Journal of Market Access & Health Policy
article-version (VoR) Version of Record
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
article-version (VoR) Version of Record
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
Background: Gene therapies can treat, prevent, or cure a disease by changing the expression of a person’s genes. They are an innovative strategy for treating genetic disorders; however, they are still emerging on the market access and in the health
Autor:
Michal Pochopien, Jakub Wladyslaw Dziedzic, Samuel Aballea, Emilie Clay, Iwona Zerda, Mondher Toumi, Borislav Borissov
Publikováno v:
Journal of Market Access & Health Policy, Vol 12, Iss 2, Pp 35-57 (2024)
Objective: Currently there are no disease-specific approved therapies for non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH); however, several treatments are under development. This study aimed to estimate the cost-effectivenes
Externí odkaz:
https://doaj.org/article/fc390ad500dc455d81017d8d018d9062
Autor:
Phil McEwan, Samuel Aballéa, Annette Beiderbeck, Michał Pochopień, Richard Zur, Mondher Toumi
Publikováno v:
BMC Health Services Research, Vol 19, Iss 1, Pp 1-14 (2019)
BMC Health Services Research
BMC Health Services Research
Background Diabetic macular oedema (DMO) may lead to visual loss and blindness. Several pharmacological treatments are available on the National Health Service (NHS) to United Kingdom patients affected by this condition, including intravitreal vascul